A global examination of allometric scaling for predicting human drug clearance and the prediction of large vertical allometry

被引:73
作者
Tang, Huaidong [1 ]
Mayersohn, Michael [1 ]
机构
[1] Univ Arizona, Coll Pharm, Dept Pharmaceut Sci, Tucson, AZ 85721 USA
关键词
allometric scaling; vertical allometry; clearance; protein binding; C logP;
D O I
10.1002/jps.20481
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Allometrically scaled data sets (138 compounds) used for predicting human clearance were obtained from the literature. Our analyses of these data have led to four observations. (1) The current data do not provide strong evidence that systemic clearance (CLs; n = 102) is more predictable than apparent oral clearance (CLpo; n = 24), but caution needs to be applied because of potential CLpo prediction error caused by differences in bioavailability across species. (2) CL, of proteins (n = 10) can be more accurately predicted than that of non-protein chemicals (n = 102). (3) CL, is more predictable for compounds eliminated by renal or biliary excretion (n = 33) than by metabolism (n = 57). (4) CL predictability for hepatically eliminated compounds followed the order: high CL (n = 11) > intermediate CL (n = 17) > low CL (n = 29). All examples of large vertical allometry (% error of prediction greater than 1000%) occurred only when predicting human CLs of drugs having very low CLs. A qualitative analysis revealed the application of two potential rules for predicting the occurrence of large vertical allometry: (1) ratio of unbound fraction of drug in plasma (f(u)) between rats and humans greater than 5; (2) C logP greater than 2. Metabolic elimination could also serve as an additional indicator for expecting large vertical allometry. (c) 2006 Wiley-Liss, Inc.
引用
收藏
页码:1783 / 1799
页数:17
相关论文
共 162 条
[91]  
Mahmood I, 1999, BIOPHARM DRUG DISPOS, V20, P137, DOI 10.1002/(SICI)1099-081X(199904)20:3<137::AID-BDD165>3.0.CO
[92]  
2-I
[93]  
Mahmood Iftekhar, 2002, Drug Metabol Drug Interact, V19, P49
[94]  
MATSUMOTO K, 1983, ARZNEIMITTEL-FORSCH, V33-2, P961
[95]  
Matsushima H, 1998, DRUG METAB DISPOS, V26, P240
[96]   PREDICTION OF THE PHARMACOKINETICS OF CEFODIZIME AND CEFOTETAN IN HUMANS FROM PHARMACOKINETIC PARAMETERS IN ANIMALS [J].
MATSUSHITA, H ;
SUZUKI, H ;
SUGIYAMA, Y ;
SAWADA, Y ;
IGA, T ;
HANANO, M ;
KAWAGUCHI, Y .
JOURNAL OF PHARMACOBIO-DYNAMICS, 1990, 13 (10) :602-611
[97]  
MCGOVREN JP, 1988, DRUG METAB DISPOS, V16, P18
[98]   INTERSPECIES PHARMACOKINETIC SCALING OF BSH IN MICE, RATS, RABBITS, AND HUMANS [J].
MEHTA, SC ;
LU, DR .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1995, 16 (09) :735-744
[99]   The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine [J].
Milne, RW ;
Nation, RL ;
Somogyi, AA .
DRUG METABOLISM REVIEWS, 1996, 28 (03) :345-472
[100]   PREDICTION OF ACNU PLASMA CONCENTRATION-TIME PROFILES IN HUMANS BY ANIMAL SCALE-UP [J].
MITSUHASHI, Y ;
SUGIYAMA, Y ;
OZAWA, S ;
NITANAI, T ;
SASAHARA, K ;
NAKAMURA, KI ;
TANAKA, M ;
NISHIMURA, T ;
INABA, M ;
KOBAYASHI, T .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 27 (01) :20-26